Management of atrial flutter.
Typical atrial flutter is a macroreentrant arrhythmia of the right atrium. The isthmus area between the tricuspid annulus, the inferior vena cava, and the ostium of the coronary sinus is a critical zone of the reentry circle. Atrial flutter has been treated with class I and III antiarrhytmic drugs to maintain sinus rhythm, with moderate success. Catheter ablation has been highly successful in treating atrial flutter. A contiguous line of bidirectional electrical block is created in the isthmus area between the tricuspid annulus and the inferior vena cava by application of radiofrequency energy. In patients with both atrial flutter and atrial fibrillation, ablation of the atrial flutter circuit may make the atrial fibrillation more easy to control. Quality of life assessments show improvement after ablation of atrial flutter. With a probability of success of 90%, a recurrence rate of 5% to 15%, and few complications, catheter ablation emerges as the best treatment of recurrent, symptomatic flutter.
Kongsgaard
E
E
Department of Cardiology, Rikshospitalet, University Hospital of Oslo, N-0027 Oslo, Norway. erik.kongsgaard@klinmed.uio.no
Aass
H
H
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001282:Atrial Flutter / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D017115:Catheter Ablation; D022062:Electrophysiologic Techniques, Cardiac; D005424:Flecainide / Q000627:therapeutic use; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D011788:Quality of Life; D012008:Recurrence; D013015:Sotalol / Q000627:therapeutic use; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D013015:Sotalol; D005424:Flecainide